Eculizumab and ravulizumab in the treatment of refractory antiphospholipid syndrome—a first case report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Eculizumab and ravulizumab in the treatment of refractory antiphospholipid syndrome—a first case report

Published:2024-07-02 Issue: Volume: Page:
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Antovic Aleksandra¹,Faustini Francesca¹,Karandyszowska Natali²,Svenungsson Elisabet¹^ORCID,Yilmaz Esin Beste¹,Bruzelius Maria²,Gunnarsson Iva¹

Affiliation:

1. Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Rheumatology, Karolinska University Hospital , Stockholm, Sweden

2. Department of Medicine Solna, Karolinska Institutet and Coagulation Unit, Department of Hematology, Karolinska University Hospital , Stockholm, Sweden

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keae353/58499562/keae353.pdf

Reference4 articles.

1. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS);Miyakis;J Thromb Haemost,2006

2. Complement in the pathophysiology of the antiphospholipid syndrome;Chaturvedi;Front Immunol,2019

3. Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the “CAPS Registry”;López-Benjume;Autoimmun Rev,2022

4. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature;Kello;Semin Arthritis Rheum,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP